** Shares of Vertex Pharmaceuticals VRTX.O fall 5.04% to $475 premarket
** Co posted Q1 revenue of $2.77 billion, missing analyst estimates of $2.85 billion according to data compiled by LSEG
** Co raised the low end of its full-year 2025 revenue forecast range to $11.85 billion from $11.75, keeping the higher end at $12 billion
** Co saw a revenue decline in Russia where Vertex's intellectual property rights is being violated
** Street estimates may not have fully encompassed the previously disclosed impacts of an unauthorized copy of co's cystic fibrosis Trikafta in Russia - William Blair
** Reports quarterly adj profit of $4.06 per share, below estimates of $4.32
** Up to last close, stock down ~24% YTD
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。